{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:08:12Z","timestamp":1791385692154,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12325-023-02701-z","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:01:47Z","timestamp":1697259707000},"page":"5502-5518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6905-4141","authenticated-orcid":false,"given":"Anders","family":"L\u00f8kke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6014-0132","authenticated-orcid":false,"given":"Luca","family":"Castello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Pinheiro Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-6823","authenticated-orcid":false,"given":"St\u00e9phane","family":"Soulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-3463","authenticated-orcid":false,"given":"Ole","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"2701_CR1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27: 180076.","journal-title":"Eur Respir Rev"},{"key":"2701_CR2","doi-asserted-by":"publisher","first-page":"00597","DOI":"10.1183\/23120541.00597-2021","volume":"8","author":"O Hilberg","year":"2022","unstructured":"Hilberg O, Hoffmann-Vold A-M, Smith V, et al. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. ERJ Open Res. 2022;8:00597\u20132021.","journal-title":"ERJ Open Res"},{"key":"2701_CR3","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35:2015\u201324.","journal-title":"Curr Med Res Opin"},{"key":"2701_CR4","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1007\/s12325-020-01384-0","volume":"37","author":"WA Wuyts","year":"2020","unstructured":"Wuyts WA, Papiris S, Manali E, et al. The burden of progressive fibrosing interstitial lung disease: a DELPHI approach. Adv Ther. 2020;37:3246\u201364.","journal-title":"Adv Ther"},{"key":"2701_CR5","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1007\/s12325-020-01380-4","volume":"37","author":"AL Olson","year":"2020","unstructured":"Olson AL, Maher TM, Acciai V, et al. Healthcare resources utilization and costs of patients with non-IPF progressive fibrosing interstitial lung disease based on insurance claims in the USA. Adv Ther. 2020;37:3292\u20138.","journal-title":"Adv Ther"},{"key":"2701_CR6","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"2701_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163894","volume":"11","author":"VK Jaeger","year":"2016","unstructured":"Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS ONE. 2016;11:e0163894.","journal-title":"PLoS ONE"},{"key":"2701_CR8","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1093\/rheumatology\/keab154","volume":"60","author":"A-M Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold A-M, Bendstrup E, Dimitroulas T, et al. Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. Rheumatology (Oxford). 2021;60:5601\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"2701_CR9","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","volume":"200","author":"A-M Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold A-M, Fretheim H, Halse A-K, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med. 2019;200:1258\u201366.","journal-title":"Am J Respir Crit Care Med"},{"key":"2701_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.799912","volume":"9","author":"V Cottin","year":"2022","unstructured":"Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The burden of progressive-fibrosing interstitial lung diseases. Front Med (Lausanne). 2022;9:799912.","journal-title":"Front Med (Lausanne)"},{"key":"2701_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12931-021-01807-8","volume":"22","author":"PN Maqhuzu","year":"2021","unstructured":"Maqhuzu PN, Kreuter M, Bahmer T, et al. Cost drivers in the pharmacological treatment of interstitial lung disease. Respir Res. 2021;22:218.","journal-title":"Respir Res"},{"key":"2701_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/resp.14234","volume":"27","author":"M Knarborg","year":"2022","unstructured":"Knarborg M, L\u00f8kke A, Hilberg O, Ibsen R, Sikjaer MG. Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: a nationwide population-based cohort study. Respirology. 2022;27:341\u20139.","journal-title":"Respirology"},{"key":"2701_CR13","unstructured":"Eurostat. Glossary: retirement age (legal, standard, reference). https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Glossary:Retirement_age_(legal,_standard,_reference). Accessed 08 Nov 2022."},{"key":"2701_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s12325-020-01541-5","volume":"38","author":"JR Davidsen","year":"2021","unstructured":"Davidsen JR, Miedema J, Wuyts W, et al. Economic burden and management of systemic sclerosis-associated interstitial lung disease in 8 European countries: the BUILDup Delphi consensus study. Adv Ther. 2021;38:521\u201340.","journal-title":"Adv Ther"},{"key":"2701_CR15","doi-asserted-by":"publisher","first-page":"2004538","DOI":"10.1183\/13993003.04538-2020","volume":"59","author":"KR Flaherty","year":"2022","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2022;59:2004538.","journal-title":"Eur Respir J"},{"issue":"26","key":"2701_CR16","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"key":"2701_CR17","unstructured":"Eurostat. Statistics. 2022. https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/ILC_DI03__custom_1275633\/default\/table?lang=en. Accessed 28 Oct 2022."},{"key":"2701_CR18","unstructured":"Euro area and EU working days to build Calendar Adjustment Regressor. CROS - European Commission. 2016. https:\/\/ec.europa.eu\/eurostat\/cros\/content\/euro-area-and-eu-working-days-build-calendar-adjustment-regressor_en. Accessed 28 Oct 2022."},{"key":"2701_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12931-021-01749-1","volume":"22","author":"M Nasser","year":"2021","unstructured":"Nasser M, Larrieu S, Boussel L, et al. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respir Res. 2021;22:162.","journal-title":"Respir Res"},{"key":"2701_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.699532","volume":"8","author":"V Cottin","year":"2021","unstructured":"Cottin V, Larrieu S, Boussel L, et al. Epidemiology, mortality and healthcare resource utilization associated with systemic sclerosis-associated interstitial lung disease in France. Front Med (Lausanne). 2021;8:699532.","journal-title":"Front Med (Lausanne)"},{"key":"2701_CR21","unstructured":"Eurostat. Population on 1 January by age group and sex. 2021. https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/demo_pjangroup\/default\/table?lang=en. Accessed 28 Oct 2022."},{"key":"2701_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s41669-022-00354-2","volume":"6","author":"L Westerink","year":"2022","unstructured":"Westerink L, Nicolai JLJ, Postma MJ, van Boven JFM, Boersma C. Cost-effectiveness of nintedanib for patients with progressive fibrosing interstitial lung disease (PF-ILD). Pharmacoecon Open. 2022;6:647\u201356.","journal-title":"Pharmacoecon Open"},{"key":"2701_CR23","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"2701_CR24","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/art.11073","volume":"48","author":"MD Mayes","year":"2003","unstructured":"Mayes MD, Lacey JV, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246\u201355.","journal-title":"Arthritis Rheum"},{"key":"2701_CR25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685\u201399.","journal-title":"Lancet"},{"key":"2701_CR26","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s12325-019-00929-2","volume":"36","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Fan Y, Thomason D, et al. Economic burden of illness among commercially insured patients with systemic sclerosis with interstitial lung disease in the USA: a claims data analysis. Adv Ther. 2019;36:1100\u201313.","journal-title":"Adv Ther"},{"key":"2701_CR27","unstructured":"Statistica. Median household income in the United States from 1990 to 2022. 2023. https:\/\/www.statista.com\/statistics\/200838\/median-household-income-in-the-united-states\/. Accessed 05 Jun 2023."},{"key":"2701_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9:476\u201386.","journal-title":"Lancet Respir Med"},{"key":"2701_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","volume":"8","author":"TM Maher","year":"2020","unstructured":"Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8:147\u201357.","journal-title":"Lancet Respir Med"},{"key":"2701_CR30","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0075-2018","volume":"27","author":"JJ Swigris","year":"2018","unstructured":"Swigris JJ, Brown KK, Abdulqawi R, et al. Patients\u2019 perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180075.","journal-title":"Eur Respir Rev"},{"key":"2701_CR31","unstructured":"European Medicines Agency. OFEV Summary of Product Characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ofev-epar-product-information_en.pdf. Accessed 30 Apr 2023."},{"key":"2701_CR32","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A2754?role=tab","author":"JJ Swigris","year":"2020","unstructured":"Swigris JJ, Richeldi L, Wijsenbeek M, et al. Effects of nintedanib on dyspnea, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD Trial | B16 ILD THERAPY II. ATS 2020 Int Conf Am Thorac Soc Int Conf Meet Abstr. 2020. https:\/\/doi.org\/10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A2754?role=tab.","journal-title":"ATS 2020 Int Conf Am Thorac Soc Int Conf Meet Abstr"},{"key":"2701_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-001167","volume":"9","author":"JJ Swigris","year":"2022","unstructured":"Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Responsiveness and meaningful change thresholds of the living with pulmonary fibrosis (L-PF) questionnaire dyspnoea and cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ Open Respir Res. 2022;9:e001167.","journal-title":"BMJ Open Respir Res"},{"key":"2701_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1164\/rccm.201903-0614PP","volume":"200","author":"MS Wijsenbeek","year":"2019","unstructured":"Wijsenbeek MS, Holland AE, Swigris JJ, Renzoni EA. Comprehensive supportive care for patients with fibrosing interstitial lung disease. Am J Respir Crit Care Med. 2019;200:152\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2701_CR35","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","volume":"5","author":"M Kreuter","year":"2017","unstructured":"Kreuter M, Bendstrup E, Russell A-M, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5:968\u201380.","journal-title":"Lancet Respir Med"},{"key":"2701_CR36","doi-asserted-by":"publisher","first-page":"00124","DOI":"10.1183\/23120541.00124-2019","volume":"5","author":"CC Moor","year":"2019","unstructured":"Moor CC, Wijsenbeek MS, Balestro E, et al. Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Res. 2019;5:00124\u20132019.","journal-title":"ERJ Open Res"},{"key":"2701_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1753465816686743","volume":"11","author":"MJG van Manen","year":"2017","unstructured":"van Manen MJG, Geelhoed JJM, Tak NC, Wijsenbeek MS. Optimizing quality of life in patients with idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2017;11:157\u201369.","journal-title":"Ther Adv Respir Dis"},{"issue":"7","key":"2701_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fmed.2020.00029","volume":"7","author":"A Tzouvelekis","year":"2020","unstructured":"Tzouvelekis A, Karampitsakos T, Kourtidou S, et al. Impact of depression on patients with idiopathic pulmonary fibrosis. Front Med (Lausanne). 2020;7(7):29.","journal-title":"Front Med (Lausanne)"},{"key":"2701_CR39","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1177\/0269216317701890","volume":"31","author":"L Brereton","year":"2017","unstructured":"Brereton L, Clark J, Ingleton C, et al. What do we know about different models of providing palliative care? Findings from a systematic review of reviews. Palliat Med. 2017;31:781\u201397.","journal-title":"Palliat Med"},{"key":"2701_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104766","volume":"95","author":"T Karampitsakos","year":"2023","unstructured":"Karampitsakos T, Juan-Guardela BM, Tzouvelekis A, Herazo-Maya JD. Precision medicine advances in idiopathic pulmonary fibrosis. EBioMedicine. 2023;95:104766.","journal-title":"EBioMedicine"},{"key":"2701_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10198-019-01119-1","volume":"21","author":"AU Rehman","year":"2020","unstructured":"Rehman AU, Hassali MAA, Muhammad SA, Harun SN, Shah S, Abbas S. The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. Eur J Health Econ. 2020;21:181\u201394.","journal-title":"Eur J Health Econ"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02701-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02701-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02701-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T07:11:14Z","timestamp":1698390674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02701-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2701"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02701-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"31 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is supported and funded by Boehringer Ingelheim. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of the manuscript. Stephane Soulard and Pedro Pinheiro Martins are employees of Boehringer Ingelheim. Boehringer Ingelheim compensated AdRes HE&OR to do the analysis. Anders Lokke, Luca Castello, and Ole Hilberg have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is based on previously published data. No ethics committee approval was required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}